Purinergic receptors, also known as purinoceptors, are a family of newly characterized plasma membrane molecules involved in several and as yet only partially known cellular functions such as vascular reactivity, apoptosis and cytokine secretion.
Little is known about the effect extracellular microenvironment has on their function.
Fibroblasts share several features with smooth muscle cells and are an important constituent of the atherosclerotic plaque.
These receptors have their effect of high glucose concentration on ATP-mediated responses in human fibroblasts.
The members of the family include the following:
| Name | Activation | Class |
| P1 receptors | adenosine | G protein-coupled receptors |
| P2Y receptors | nucleotides | G protein-coupled receptors |
| P2X receptors | ATP | ligand-gated ion channel |
Inhibitors
Inhibitors of purinergic receptors include clopidogrel, prasugrel and ticlopidine, as well as the investigational drug ticagrelor. All of these are antiplatelet agents that block P2Y12 receptors.
External links
- IUPHAR GPCR Database - Adenosine receptors
- IUPHAR GPCR Database - P2Y receptors
- MeSH Purinergic+Receptors
 |
This transmembrane receptor-related article is a stub. You can help Wikipedia by expanding it. |
|
||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||
This entry is from Wikipedia, the leading user-contributed encyclopedia. It may not have been reviewed by professional editors (see full disclaimer)
